N. Anthony Coles, CEO and Chairperson at Cerevel Therapeutics Holdings, Inc. (CERE), sold 99,700 shares at $31.36 ($3.1M) on 2023-05-04, disclosed to the SEC on 2023-05-08.
Scheduled sale ($3.1M) by CEO and Chairperson under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $31.36 | 37,568 | $1.2M | 37.6% |
| 2 | $31.36 | 37,568 | $1.2M | 37.6% |
| 3 | $31.76 | 12,132 | $385K | 12.3% |
| 4 | $31.76 | 12,132 | $385K | 12.3% |
| 5 | $32.93 | 300 | $10K | 0.3% |
| Total | $31.46 avg | 99,700 |
| $3.1M |
| 100% |
| Filing → |
| CERE | SELL | 2024-05-14 | $2.1M | — | Filing → |
| CERE | SELL | 2024-04-03 | $2.1M | — | Filing → |
| CERE | SELL | 2024-03-06 | $2.1M | — | Filing → |